Potassium channel inhibitors
View Patent ↗The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
1. A compound selected from the group consisting of:
N,N-diisopropyl-3-phenyl-4-[(4-phenylbutanoyl)amino]-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-3-phenyl-4-[({[(1S)-1-phenylethyl]amino}carbonyl)amino]-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-3-phenyl-4-[(3-phenylpropanoyl)amino]-2-pyridin-3-ylbutanamide,
4-{([3-(2-fluorophenyl)propanoyl]amino}-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-3-phenyl-4-[(3-phenylbutanoyl)amino]-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-4-({[(3-methylbenzyl)amino]carbonyl}amino)-3-phenyl-2-pyridin-3-ylbutanamide,
4-({[(4-bromobenzyl)amino]carbonyl}amino)-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
4-({[(4-fluorobenzyl)amino]carbonyl}amino)-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-3-phenyl-4-[({[(1R,2S)-2-phenylcyclopropyl]amino}carbonyl)amino]-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-4-[({[1-(1-naphthyl)ethyl]amino}carbonyl)amino]-3-phenyl-2-pyridin-3-ylbutanamide,
4-({[(3-fluorobenzyl)amino]carbonyl}amino)-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
4-[(benzylsulfonyl)amino]-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-4-({[(4-methylbenzyl)amino]carbonyl}amino)-3-phenyl-2-pyridin-3-ylbutanamide,
4-({[(2-fluorobenzyl)amino]carbonyl}amino)-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-3-phenyl-4-{[(2-phenyl-1,3-thiazol-4-yl)acetyl]amino}-2-pyridin-3-ylbutanamide,
4-{[3-(2-chlorophenyl)propanoyl]amino}-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-4-({[(4-methoxybenzyl)amino]carbonyl}amino)-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-3-phenyl-4-({[(E)-2-phenylvinyl]sulfonyl}amino)-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-3-phenyl-2-pyridin-3-yl-4-({[2-(trifluoromethyl)phenyl]sulfonyl}amino)butanamide,
N,N-diisopropyl-3-phenyl-2-pyridin-3-yl-4-[(3-pyridin-2-ylpropanoyl)amino]butanamide,
N,N-diisopropyl-3-phenyl-4-({[(2-phenylethyl)amino]carbonyl}amino)-2-pyridin-3-ylbutanamide,
4-({[(2-chlorobenzyl)amino]carbonyl}amino)-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
4-{[(cyclohexylamino)carbonyl]amino}-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
4-({[(3-fluorophenyl)amino]carbonyl}amino)-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-4-{[(1-naphthylamino)carbonyl]amino}-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-3-phenyl-4-[({[(1R)-1-phenylethyl]amino}carbonyl)amino]-2-pyridin-3-ylbutanamide,
4-({[(diphenylmethyl)amino]carbonyl}amino)-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-3-phenyl-4-[({[(1S)-1-phenylethyl]amino}carbonyl)amino]-2-pyridin-3-ylbutanamide,
4-{[(sec-butylamino)carbonyl]amino}-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
4-({[(diphenylmethyl)amino]carbonyl}amino)-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
4-[(2,3-dihydro-1H-inden-2-ylacetyl)amino]-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
4-(acetylamino)-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-3-phenyl-2-pyridin-3-yl-4-({[2-(trifluoromethyl)phenyl]acetyl}amino)butanamide,
4-{[(2-chloro-6-fluorophenyl)acetyl]amino}-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
N-[4-(diisopropylamino)-4-oxo-2-phenyl-3-pyridin-3-ylbutyl]pentanamide,
N,N-diisopropyl-4-{[3-(1-methyl-1H-pyrazol-4-yl)propanoyl]amino}-3-phenyl-2-pyridin-3-ylbutanamide,
methyl 5-{[2-(1,3-benzodioxol-5-yl)ethyl]amino}-5-oxo-3-phenyl-4-pyridin-3-ylpentanoate,
N 5 -(2-fluorobenzyl)-N 1 ,N 1 -diisopropyl-3-phenyl-2-pyridin-3-ylpentanediamide,
N 1 ,N 1 -diisopropyl-3-phenyl-N 5 -(3-phenylpropyl)-2-pyridin-3-ylpentanediamide,
N 1 ,N 1 -diisopropyl-3-phenyl-N 5 -(1-phenylethyl)-2-pyridin-3-ylpentanediamide,
N 5 -[2-(tert-butylthio)ethyl]-N 1 ,N 1 -diisopropyl-3-phenyl-2-pyridin-3-ylpentanediamide,
N 1 ,N 1 -diisopropyl-3-phenyl-N 5 -(2-phenylethyl)-2-pyridin-3-ylpentanediamide,
N 5 -(2,3-dihydro-1H-inden-2-yl)-N 1 ,N 1 -diisopropyl-3-phenyl-2-pyridin-3-ylpentanediamide,
N 1 ,N 1 -diisopropyl-3-phenyl-N 5 -[(4-phenylmorpholin-2-yl)methyl]-2-pyridin-3-ylpentanediamide,
N 1 ,N 1 -diisopropyl-3-phenyl-N 5 -pyridin-2-yl-2-pyridin-3-ylpentanediamide,
N 1 ,N 1 -diisopropyl-N 5 -(1-isopropyl-2-methylpropyl)-3-phenyl-2-pyridin-3-ylpentanediamide,
N 5 -(1H-benzimidazol-2-ylmethyl)-N 1 ,N 1 -diisopropyl-3-phenyl-2-pyridin-3-ylpentanediamide,
N 5 -(3-isopropoxypropyl)-N 1 ,N 1 -diisopropyl-3-phenyl-2-pyridin-3-ylpentanediamide,
N 1 ,N 1 -diisopropyl-3-phenyl-2-pyridin-3-yl-N-5-(pyridin-2-ylmethyl)pentanediamide,
methyl 5-{[5-(diisopropylamino)-5-oxo-3-phenyl-4-pyridin-3-ylpentanoyl]amino}pentanoate,
1-tert-butyl 5-methyl 3-phenyl-2-pyridin-3-ylpentanedioate,
methyl 4-(3-cyanophenyl)-5-(diisopropylamino)-5-oxo-3-pyridin-3-ylpentanoate,
methyl 4-(3-bromophenyl)-5-(diisopropylamino)-5-oxo-3-pyridin-3-ylpentanoate,
N 1 ,N 1 -diisopropyl-N 5 ,N 5 -dimethyl-3-phenyl-2-pyridin-3-ylpentanediamide,
N 1 ,N 1 -diisopropyl-N 5 -methyl-3-phenyl-2-pyridin-3-ylpentanediamide,
methyl 5-(diisopropylamino)-5-oxo-4-pyridin-3-yl-3-pyridin-4-ylpentanoate,
5-methoxy-5-oxo-3-phenyl-2-pyridin-3-ylpentanoic acid,
methyl 5-(diisopropylamino)-5-oxo-4-pyridin-3-yl-3-pyridin-4-ylpentanoate,
methyl 5-(diisopropylamino)-5-oxo-3-phenyl-4-pyridin-2-ylpentanoate,
methyl 5-(diisopropylamino)-5-oxo-4-pyridin-2-yl-3-pyridin-4-ylpentanoate,
methyl 5-(diisopropylamino)-5-oxo-3,4-dipyridin-4-ylpentanoate,
methyl 5-(diisopropylamino)-5-oxo-4-phenyl-3-pyridin-4-ylpentanoate,
methyl 5-(diisopropylamino)-5-oxo-3-phenyl-4-pyridin-4-ylpentanoate,
3-(3-cyanophenyl)-4-({[(2-fluorobenzyl)amino]carbonyl}amino)-N,N-diisopropyl-2-pyridin-3-ylbutanamide,
N-[4-(diisopropylamino)-4-oxo-2-phenyl-3-pyridin-3-ylbutyl]-2-fluoro-N-(methylsulfonyl)phenylalaninamide,
N-[4-(diisopropylamino)-4-oxo-2-phenyl-3-pyridin-3-ylbutyl]-2-fluorophenylalaninamide,
N-(tert-butoxycarbonyl)-N-[4-(diisopropylamino)-4-oxo-2-phenyl-3-pyridin-3-ylbutyl]-2-fluorophenylalaninamide,
N,N-diisopropyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-4-(2-methyl-2H-tetrazol-5-yl)-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-4-(1-methyl-1H-tetrazol-5-yl)-3-phenyl-2-pyridin-3-ylbutanamide,
5-hydrazino-N,N-diisopropyl-5-oxo-3-phenyl-2-pyridin-3-ylpentanamide,
N,N-diisopropyl-4-(3-methyl-1,2,4-oxadiazol-5-yl)-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-4-(5-methyl-1,3-oxazol-2-yl)-3-phenyl-2-pyridin-3-ylbutanamide,
4-cyano-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-4-[(methylsulfonyl)amino]-3-phenyl-2-pyridin-3-ylbutanamide,
N,N-diisopropyl-4-(5-methyl-1,3-oxazol-2-yl)-3-phenyl-2-pyridin-3-ylbutanamide,
5-hydroxy-N,N-diisopropyl-3-phenyl-2-pyridin-3-ylpentanamide,
tert-butyl 4-(diisopropylamino)-4-oxo-2-phenyl-3-pyridin-3-ylbutylcarbamate,
methyl 3-(3-cyanophenyl)-5-(diisopropylamino)-5-oxo-4-pyridin-3-ylpentanoate,
methyl 3-(3-bromophenyl)-5-(diisopropylamino)-5-oxo-4-pyridin-3-ylpentanoate,
5-(diisopropylamino)-5-oxo-3-phenyl-4-pyridin-3-ylpentanoic acid,
N 1 ,N 1 -diisopropyl-3-phenyl-2-pyridin-3-ylpentanediamide,
methyl 5-(diisopropylamino)-5-oxo-4-phenyl-3-pyridin-3-ylpentanoate,
methyl 5-(diisopropylamino)-5-oxo-4-pyridin-2-yl-3-pyridin-3-ylpentanoate,
methyl 5-(diisopropylamino)-5-oxo-4-pyridin-2-yl-3-pyridin-3-ylpentanoate,
methyl 5-(diisopropylamino)-5-oxo-4-phenyl-3-pyridin-3-ylpentanoate,
methyl 5-(diisopropylamino)-5-oxo-3-phenyl-4-pyridin-3-ylpentanoate,
methyl 5-(diisopropylamino)-5-oxo-3,4-dipyridin-3-ylpentanoate,
methyl 5-(diisopropylamino)-3-(6-methoxypyridin-3-yl)-5-oxo-4-phenylpentanoate,
methyl 5-(diisopropylamino)-5-oxo-3-pyridin-2-yl-4-pyridin-4-ylpentanoate,
methyl 5-(diisopropylamino)-5-oxo-3-pyridin-2-yl-4-pyridin-3-ylpentanoate,
methyl 5-(diisopropylamino)-5-oxo-3,4-dipyridin-2-ylpentanoate, and
methyl 5-(diisopropylamino)-5-oxo-4-phenyl-3-pyridin-2-ylpentanoate, or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical formulation comprising a pharmaceutically acceptable carrier and the compound of claim 1 .
3. A pharmaceutical composition made by combining the compound of claim 1 and a pharmaceutically acceptable carrier.
4. A method of treating cardiac arrythmia comprising administering a compound of claim 1 with a compound selected from one of the classes of compounds consisting of antiarrhythmic agents having Kv1.5 blocking activities, ACE inhibitors, angiotensin II antagonists, cardiac glycosides, L-type calcium channel blockers, T-type calcium channel blockers, selective and nonselective beta blockers, endothelin antagonists, thrombin inhibitors, aspirin, nonselective NSAIDs, warfarin, factor Xa inhibitors, low molecular weight heparin, unfractionated heparin, clopidogrel, ticlopidine, IIb/IIIa receptor antagonists, 5HT receptor antagonists, integrin receptor antagonists, thromboxane receptor antagonists, TAFI inhibitors and P2T receptor antagonists.